- Home
- CDNA vs AAMI Comparison
CDNA vs AAMI Comparison
Compare CDNA & AAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- AAMI
- Stock Information
- Founded
- CDNA 1998
- AAMI 1980
- Country
- CDNA United States
- AAMI United States
- Employees
- CDNA N/A
- AAMI N/A
- Industry
- CDNA Medical Specialities
- AAMI Investment Managers
- Sector
- CDNA Health Care
- AAMI Finance
- Exchange
- CDNA Nasdaq
- AAMI Nasdaq
- Market Cap
- CDNA 1.1B
- AAMI 964.3M
- IPO Year
- CDNA 2014
- AAMI N/A
- Fundamental
- Price
- CDNA $23.34
- AAMI N/A
- Analyst Decision
- CDNA Buy
- AAMI
- Analyst Count
- CDNA 8
- AAMI 0
- Target Price
- CDNA $27.17
- AAMI N/A
- AVG Volume (30 Days)
- CDNA 642.2K
- AAMI 226.9K
- Earning Date
- CDNA 02-26-2025
- AAMI 01-30-2025
- Dividend Yield
- CDNA N/A
- AAMI 0.16%
- EPS Growth
- CDNA N/A
- AAMI N/A
- EPS
- CDNA N/A
- AAMI 1.65
- Revenue
- CDNA $312,775,000.00
- AAMI $469,000,000.00
- Revenue This Year
- CDNA $19.85
- AAMI N/A
- Revenue Next Year
- CDNA $11.34
- AAMI N/A
- P/E Ratio
- CDNA N/A
- AAMI $15.60
- Revenue Growth
- CDNA 5.26
- AAMI 12.17
- 52 Week Low
- CDNA $7.42
- AAMI $18.31
- 52 Week High
- CDNA $34.84
- AAMI $31.52
- Technical
- Relative Strength Index (RSI)
- CDNA 56.42
- AAMI N/A
- Support Level
- CDNA $20.35
- AAMI N/A
- Resistance Level
- CDNA $21.68
- AAMI N/A
- Average True Range (ATR)
- CDNA 1.10
- AAMI 0.00
- MACD
- CDNA 0.19
- AAMI 0.00
- Stochastic Oscillator
- CDNA 99.09
- AAMI 0.00
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.